AlphaStocks
3.8
Weak

VERACYTE, INC. (VCYT)

Health Care / Health Care Services

S&P SmallCap 600

$32.43

Scores poorly across most models. Proceed with caution.

Weak

Score based on 3 of 5 models — moderate confidence

#895out of 1127 in Health Care

Is VERACYTE, INC. a Good Investment in 2026?

VERACYTE, INC. (VCYT) scores 3.8 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates VERACYTE, INC. as Strong (7/9). However, the Graham model rates it Caution — 55% above fair value. VERACYTE, INC. currently trades above its estimated fair value of $20, suggesting limited upside at current prices. VERACYTE, INC. ranks #895 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E39.4ROE3.9Market Cap3B

Estimated Fair Value

$19.5166% above

Trading above estimated fair value. P/e of 39x implies high growth expectations. rapid eps growth (167%) partially justifies the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

55% above fair value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is VERACYTE, INC. (VCYT) a good investment?
Based on AlphaStocks' composite analysis, VERACYTE, INC. (VCYT) scores 3.8 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading above estimated fair value. P/e of 39x implies high growth expectations. rapid eps growth (167%) partially justifies the premium.
What is VERACYTE, INC.'s Piotroski F-Score?
VERACYTE, INC.'s Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is VCYT overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $20, VCYT appears overvalued. The stock currently trades 66% above its estimated fair value. Trading above estimated fair value. P/e of 39x implies high growth expectations. rapid eps growth (167%) partially justifies the premium.
How does VCYT compare to other Health Care stocks?
VERACYTE, INC. ranks #895 out of 1127 stocks in the Health Care sector, placing it in the top 79% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about VCYT?
AlphaStocks evaluates VCYT using five proven investment models. Piotroski: Strong; Buffett: Neutral; Graham: Caution. These models are combined into a single composite score of 3.8/10.

Similar Stocks

PARRFTIAZN

Compare VCYT with

VCYT vs PARRVCYT vs FTIVCYT vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer